Royer Animal Health Enters Into Exclusive Agreement With MWI Veterinary Supply for U.S. Distribution of Next-Generation Therapeutics to Treat Cancer and ...( FREDERICK Md. April 30 /- Royer Anima...),Health

FREDERICK, Md., April 30 /PRNewswire/ -- Royer Animal Health, LLC, a wholly owned subsidiary of Royer Biomedical, Inc., has executed an exclusive distribution agreement with MWI Veterinary, Supply, Inc. (Nasdaq: MWIV) to market its lead animal health products: MATRIX III CISPLATIN BEADS and R-GEL ANTIBIOTIC WOUND DRESSING. These proprietary, timed-release products provide veterinary professionals with localized treatment options for cancer, infections, and general wound management.

By providing locally controlled delivery and increased drug concentration, Royer Animal Health therapies have proven to be highly effective, with no systemic side effects. These innovative products have only recently become available, they are currently being used in over 600 veterinary clinics and by 40 veterinary schools / teaching hospitals worldwide.

MATRIX III CISPLATIN BEADS have been clinically proven highly effective in the treatment of certain cancers with tumor rates of less than 10% reported. These fully-resorbable, [3 mm] Cisplatin Bead implants are indicated for use in the local control of equine sarcoids; clinical studies have also shown the effective use of Matrix III Cisplatin Beads in other tumor types including: melanoma, squamous cell, carcinoma and osteosarcoma. The product is safe, easy to use and manufactured under FDA -compliant conditions and represent a major breakthrough in cost-effective veterinary chemotherapy."

R-GEL ANTIBIOTIC WOUND DRESSING, is a timed-release antibiotic gel that solidifies in situ. It provides a sustained therapeutic dose of amikacin and clindamycin at the site of administration for a period of 7-9 days. The R-GEL matrix is biodegradable and fully resorbed in about 4 weeks. R-GEL has proven to be highly effective in the treatment of a wide range of small and lar
'/>"/>